Unlocking Autophagy: How USP1 Could Revolutionize Cancer Therapy
"Scientists discover how targeting a specific protein, USP1, can control cellular cleaning processes, offering new hope for treating cancer and other diseases."
Imagine your body's cells as tiny cities, constantly working, building, and producing waste. Just like any city, they need a clean-up crew to remove the trash and recycle valuable materials. This crucial process is called autophagy, a cellular 'self-eating' mechanism where damaged components are broken down and reused. Autophagy is essential for maintaining cellular health, preventing disease, and even influencing how our bodies respond to treatments like cancer therapy.
Scientists have long been fascinated by autophagy and its potential to fight various diseases. Recent studies have focused on understanding the intricate controls that govern this process, identifying key proteins that act as switches and regulators. Among these proteins, Ubiquitin Specific Peptidase 1 (USP1) has emerged as a promising target for manipulating autophagy.
A groundbreaking study published in 'Autophagy' sheds light on how USP1 regulates a core component of autophagy called ULK1. The research unveils that USP1 targets ULK1, influencing its location within the cell and its ability to initiate the autophagy process. This discovery opens up exciting possibilities for developing new therapies that harness the power of autophagy to combat diseases like cancer.
USP1 Elevation Correlates with Poor Survival and Drives Autophagy in Cancer
USP1 is significantly elevated in pancreatic ductal adenocarcinoma (PDAC) and its expression inversely correlates with overall patient survival. Depletion or inhibition of USP1 suppresses cell proliferation, epithelial–mesenchymal transition, and migration in PDAC cells while simultaneously reducing both autophagy initiation and autophagic flux. In hepatocellular carcinoma (HCC), targeting USP1 in combination with autophagy inhibitors and sorafenib has been proposed as a promising therapeutic strategy. The ubiquitin-specific protease (USP) family broadly regulates autophagy, metabolism, immune responses, and tumor resistance to drugs, with USP1 inhibition activating ER stress, increasing AMPK phosphorylation, and altering levels of key autophagy proteins including ATG5, ATG13, ULK1, and LC3.
Gaps in Current Autophagy Monitoring and USP-Targeted Strategies
Historical challenges in mammalian autophagy research have been partially addressed through advances in molecular methods, yet current assays for monitoring autophagy each carry distinct advantages and disadvantages that complicate high-throughput screening for autophagy-modulating drugs. Most existing therapeutic strategies have focused narrowly on either USP inhibitors or autophagy inhibitors as standalone anticancer approaches, with limited attention to the mechanistic interplay between the USP family and autophagy regulation. This gap underscores the need for integrated approaches that simultaneously target deubiquitinating enzymes and autophagic pathways.
Early Insights into USP1 and Autophagy Intersections
Foundational work on deubiquitinating enzymes established the USP family as critical regulators of protein homeostasis, with early studies identifying ubiquitin-specific proteases as modulators of DNA repair and cell cycle progression. The discovery of autophagy as a conserved lysosomal degradation pathway in the 1990s and the subsequent identification of ATG proteins provided the molecular framework for understanding how deubiquitination might intersect with autophagic flux. However, the specific role of USP1 in directly regulating autophagy machinery remained unexplored until recent investigations began mapping its substrates within the autophagy initiation complex.
What is USP1 and Why Does It Matter for Autophagy?
USP1, or Ubiquitin Specific Peptidase 1, belongs to a family of enzymes called deubiquitinases (DUBs). These enzymes are responsible for removing ubiquitin, a small protein that acts like a tag, marking other proteins for degradation or modification. By removing ubiquitin tags, USP1 can stabilize proteins, change their function, or alter their location within the cell.
- Location, Location, Location: USP1 influences where ULK1 resides within the cell. When USP1 is depleted or inhibited, ULK1 tends to form aggregates and relocate to specific compartments.
- Canonical vs. Non-Canonical Autophagy: USP1 plays a role in determining which type of autophagy occurs. Canonical autophagy is the traditional, well-understood pathway, while non-canonical autophagy involves alternative routes and mechanisms.
- Collaboration with SQSTM1: USP1's activity affects the interaction between ULK1 and SQSTM1, a protein that helps to recognize and deliver cargo for degradation during autophagy.
USP1 Identified as First Deubiquitinase Regulating ATG14 and Autophagy in PDAC
Recent single-cell RNA sequencing advances are enabling molecular characterization of autophagy across diverse human diseases, providing unprecedented resolution for autophagy research. A landmark 2025 study identified USP1 as the first deubiquitinase to modulate ATG14 deubiquitination, unveiling a direct regulatory role for USP1 in autophagy initiation and PDAC progression. This discovery positions USP1 as a pivotal node linking deubiquitination to the core autophagy machinery, with therapeutic implications for pancreatic cancer where autophagy is hyperactivated.
Limitations and Unresolved Questions in USP1-Autophagy Targeting
Despite promising preclinical data, the therapeutic window for USP1 inhibition remains incompletely defined, as systemic USP1 suppression may impair normal DNA repair and genomic stability in healthy tissues. Early studies have not fully addressed whether cancer cells develop compensatory resistance mechanisms through parallel deubiquitinases or alternative autophagy induction pathways. Additionally, the context-dependent dual roles of autophagy as both tumor-suppressive and tumor-promoting complicate predictions of clinical efficacy across cancer types and stages.
USP1 Versus Other Deubiquitinases and DNA Repair Targets in Autophagy Modulation
While USP1 regulates autophagy through ATG14 deubiquitination in PDAC, other deubiquitinases such as UCH-L11 promote autophagy via Beclin-1 stabilization, highlighting distinct substrate specificities within the USP family. Head-to-head comparisons of USP1 inhibitors against established DNA repair inhibitors are becoming critical as multiple USP1 inhibitors advance through clinical trials, with their relative performance defining future roles in oncology. The convergence of USP1 inhibition with autophagy modulation represents a mechanistically distinct strategy compared to direct autophagy inhibitors or conventional DNA damage response targeting.
A New Strategy for Cancer Treatment?
The study also highlights the potential for targeting USP1 in cancer therapy. The researchers found that inhibiting USP1 with a drug called pimozide affected the growth of breast cancer cells. This suggests that in tumors where autophagy plays a critical role in survival, targeting USP1 could be a valuable therapeutic strategy. By manipulating autophagy, scientists hope to disrupt cancer cells' ability to adapt and resist treatment, ultimately leading to more effective therapies.
Combinatorial USP1 Inhibition Shows Enhanced Preclinical Efficacy
Preclinical evidence demonstrates that the USP1 inhibitor ML-323, when combined with the autophagy inhibitor chloroquine and the clinical chemotherapy agent sorafenib, achieves superior inhibition of hepatocellular carcinoma growth compared to single-agent approaches. This triple-combination strategy leverages USP1-mediated ER stress induction alongside autophagy blockade and standard-of-care chemotherapy, providing a mechanistic rationale for multi-targeted regimens in liver cancer.
Clinical Pipeline Expansion and Translational Momentum for USP1 Inhibitors
Multiple USP1 inhibitors — including SIM0501, XL309–101, and HSK39775 — have entered early clinical development, signaling rapid translation from target validation to human trials. This expanding pipeline reflects growing confidence in USP1 as a therapeutic target in oncology, with ongoing preclinical work continuing to elucidate the molecular mechanisms by which USP1 regulates autophagy and DNA repair. Emerging research on USP1's role in cellular recycling pathways suggests that manipulating this axis could yield innovative cancer treatments that exploit tumor-specific vulnerabilities in protein homeostasis.
Translational Hurdles in Targeting Ubiquitin-Autophagy Crosstalk
The broader therapeutic landscape faces systemic challenges in developing USP1-targeted therapies, including the need for biomarkers that reliably report on-target USP1 inhibition and autophagic flux modulation in patients. Tumor heterogeneity and dynamic adaptation of autophagy pathways may limit durable responses to single-agent approaches. Additionally, the pleiotropic functions of USP1 in DNA repair, replication stress response, and autophagy necessitate careful patient stratification and combination regimen design to maximize therapeutic index while minimizing on-target toxicities in normal proliferating tissues.
Autophagy Modulation in Viral Pathogenesis Illustrates Cellular Stakes
Research on Japanese Encephalitis virus demonstrates that UAF1, a USP1-associated factor, modulates autophagy as part of the host-pathogen interaction, with GFP-RFP-LC3 flux assays revealing how viral infection hijacks cellular recycling machinery. This finding underscores that the USP1-autophagy axis operates not only in cancer but also in infectious disease, highlighting the fundamental importance of deubiquitination-regulated autophagy in human health and disease. Understanding these mechanisms in diverse pathological contexts may inform therapeutic strategies that preserve essential autophagic functions while targeting disease-specific dysregulation.